Scinai Immunotherapeutics Ltd. SCNI
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is an immunology/inflammation drug developer. Its lead program, NanoAbs (VHH antibody fragment) pipeline; PC111 (option to acquire), is in Pre-clinical for inflammation and immunology; severe dermatological conditions.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PC111 (fully human mAb; Pincell acquisition option) | severe dermatological conditions (keratinocyte cell death / inflammation) | antibody | Pre-clinical |
| NanoAbs platform programs incl. IL-17 (strategy under review) | inflammation and immunology | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical immunology/inflammation companies
- Adma Biologics, Inc. ADMA
- CDT Equity Inc. CDT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.